株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

抗体薬剤複合体:技術および世界市場

Antibody Drug Conjugates: Technologies and Global Markets

発行 BCC Research 商品コード 296130
出版日 ページ情報 英文 132 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.77円で換算しております。

2016年12月31日まで 年末キャンペーン割引: BCC Research社発行レポート
ご注意: ショッピングカートでは適用されませんので、割引価格についてはお問い合わせください

Back to Top
抗体薬剤複合体:技術および世界市場 Antibody Drug Conjugates: Technologies and Global Markets
出版日: 2014年02月14日 ページ情報: 英文 132 Pages
担当者のコメント
BCC Research社のレポートは、Reuter、Wall Street Journal、Fortuneなどで引用されることも多く、それぞれの業界の識者の意見として重きを置かれています。同社レポートを複数冊ご購入の場合年間パッケージのご契約がお得です。詳細は右の担当者のおすすめ商品よりご覧下さい。
概要

世界の抗体薬剤複合体(ADC)市場は2012年に1億7,900万米ドルに、2013年には3億9,600万米ドルに達しました。同市場は今後もCAGR48.1%で拡大し、2018年には28億米ドルとなる見込みです。

当レポートでは、世界のADC市場の概要と過去2年間の実績と今後5年間の予測、市場の課題、法規制のハードルなどについてまとめ、企業のプロファイルとともに、概略下記の構成で取り上げております。

第1章 イントロダクション

第2章 サマリー

第3章 抗体薬剤クラスにおけるADCの概要

  • 認可済みADC
  • ADCのルーツ:薬剤クラスとしての抗体
  • ADCの構成要素
  • ADCのための主な抗原標的
  • 新たな抗体治療法
  • ナノボディとその他の新たな抗体形態
    • ナノボディ
    • 抗体フラグメント
    • 二重特異性抗体
    • 抗体の技術革新
    • ADCの差別化側面
    • 生産

第4章 ADC市場予測

  • 医薬品市場環境
  • ADC市場環境
    • 主な促進因子
    • 主な課題
    • 成長と流通
  • 法規制要因
  • 投資と提携
  • 開発検討事項
  • 特許取得
  • 有望治療法

第5章 企業プロファイル

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: PHM161A

The global market for ADC drugs reached $179 million in 2012 and $396 million in 2013. The market should reach $2.8 billion in 2018 with a compound annual growth rate (CAGR) of 48.1%.

This report provides:

  • An overview of the global market for ADCs as a part of the pharmaceutical industry that is looking for innovative technologies.
  • Analyses of global market trends, with data from 2012, 2013, and projections of compound annual growth rates (CAGRs) through 2018.
  • Examination of key market drivers and challenges.
  • Insight into regulatory hurdles and how to meet them, as well as discussion of the drugs (and the companies behind them) that have received approval.

STUDY BACKGROUND

As the pharmaceutical industry grows, it is trying to find more ways to successfully combat disorders and disease, whether through different chemistries with novel mechanisms of action or new therapeutic areas. Companies realize they can only survive for so long by creating similar drugs to competitors where, for example, market share might be shared or by acquiring or merging with competitors. Indeed, effective companies realize they might find new ways of running their businesses at their core and that is through the science behind their products.

Antibody drug conjugates (ADCs) represent that new science and turf that pharmaceutical companies want. They are attractive too because they are targeted to certain cells, sparing other tissue and reducing side effects. ADCs consist of the merging by technology, which will be described in the report, of a monoclonal antibody (mAb), a linker and some sort of cytotoxic agent that kills that which it is designed to. The drug, because it is an antibody, binds to an antigen and induces an immune response, but it also contains a cytotoxin for the selected area, enabling a greater kill effect.

STUDY GOAL AND OBJECTIVES

The present study meets this need by focusing on the global market for ADCs in light of the most recent available information. In addition to looking at future and current markets for a wide variety of new, reformulated and established products, the study will analyze technological, environmental, legal/regulatory and socioeconomic developments that may influence the market for ADC drugs.

This report provides an analysis of the emerging ADC industry and markets, geographically and by therapeutic area. The future of ADC drugs will also be discussed.

The following topics will be discussed in the report:

  • The technology and where it fits into the pharmaceutical industry.
  • The key drivers and challenges.
  • Key considerations including regulatory hurdles.
  • Analysis of commercialized ADCs and those in the development pipeline.
  • Analysis of development and alliance deals.
  • Summaries of companies in the ADC industry.
  • Financial sales figures and projections out to 2018 including compound annual growth rates (CAGRs) will appear for the aforementioned information.

The report has been written for the entire pharmaceutical community but is tailored especially for readers with an interest in the marketing, management and public policy dimensions of ADC drugs, including readers in the following:

  • The pharmaceuticals industry, especially companies planning to enter this field.
  • Medial research institutions.
  • International organizations and governmental organizations with relevant responsibilities such as health, drug safety, conservation and the environment, and foreign trade.
  • Investors.
  • The financial and analyst community.

SCOPE OF REPORT

This report is an analytical business tool whose primary purpose is to describe the ADC drug industry.

For the purposes of this report, commercialized ADCs are those drugs that are approved by the U.S. Food and Drug Administration (FDA) as new drugs that are not sold only as monoclonal antibodies (mAbs). The study's main focus is on legal, prescription-required therapeutic medicines sold in the open market. For this report, the form of an ADC involving an antibody and small-molecule cytotoxin will be viewed as the ADC of today, though acknowledgement is made in this report that ADCs will expand to encompass other forms of small-molecule drugs possibly in nanoparticle size or some other type.

The study also does not cover the following: mAbs that do not contain a linker and cytotoxic agent and, thus, do not constitute an ADC; however, novel ADC technology and novel ADC-related technology will be discussed.

Again, the format of the study is organized around the following topics:

  • Major types and applications of ADC drugs.
  • Industry structure.
  • Market size and segmentation, including breakdown of sales by therapeutic area and geographic area.
  • Market drivers.
  • Market projections through 2018.
  • Competition.
  • Observations and conclusions regarding the future of the industry.

Table of Contents

CHAPTER 1 - INTRODUCTION

  • STUDY BACKGROUND
  • STUDY GOAL AND OBJECTIVES
  • SCOPE OF REPORT
  • METHODOLOGY AND INFORMATION SOURCES
  • COMMERCIAL DRUGS
  • DEVELOPMENTAL DRUGS
    • TABLE A: FDA* APPROVAL PROCESS FOR NEW DRUGS
  • ANALYST CREDENTIALS
  • RELATED BCC RESEARCH REPORTS
  • BCC RESEARCH ONLINE SERVICES
  • DISCLAIMER

CHAPTER 2 - SUMMARY

  • SUMMARY TABLE: GLOBAL FORECAST FOR ADC DRUGS* THROUGH 2018 ($ MILLIONS)
  • SUMMARY FIGURE: GLOBAL FORECAST FOR ADC DRUGS* 2011-2018 ($ MILLIONS)

CHAPTER 3 - OVERVIEW OF ADCS WITHIN ANTIBODY DRUG CLASS

  • FIGURE 1: ADC ILLUSTRATED
  • APPROVED ADCS
    • MYLOTARG (GEMTUZUMAB OZOGAMICIN)
    • ADCETRIS (BRENTUXIMAB VEDOTIN)
    • KADCYLA (TRASTUZUMAB-DM1)
  • THE ROOTS OF ADCS: ANTIBODIES AS DRUG CLASS
    • HISTORY OF ANTIBODY DEVELOPMENT
      • TABLE 1: KEY DATES IN ANTIBODY DEVELOPMENT
    • THE MOVE TO HUMANIZATION
      • TABLE 2: CLASSES OF BIOPHARMACEUTICALS
    • ADCS AS A NEW CATEGORY
      • TABLE 3: DOMINANT ADC TECHNOLOGY
  • COMPONENTS OF ADCS
    • Antibodies
    • Linkers
    • Cytotoxins
      • TABLE 4: ADC CYTOTOXINS USED AND THEIR MODES OF ACTION
    • Calicheamicin
    • Maytansinoid
    • Auristatins (MMAE, MMAF)
    • PBDs
    • The Antigen Target
  • KEY ANTIGEN TARGETS FOR ADCS
    • HER2 (Human Epidermal Growth Factor Receptor)
    • Nectin-4
    • Mesothelin
    • GPNMB
    • PSMA
    • EGFR (Epidermal Growth Factor Receptor, also Called ErbB1)
    • VEGF (Vascular Endothelial Growth Factor)
    • CD19
    • CD20
    • CD22
    • CD25
    • CD30
    • CD33
    • CD40
    • CD56
    • CD74
    • CD79a and CD79b
    • CD138 (Syndecan 1)
    • CEACAM (also called CEA)
    • SLITRK6
    • LIV-1
    • EGP-1 (Epithelial Glycoprotein-1 Antigen, also known as TROP-2)
    • Mesothelin
  • NOVEL FORMS OF ANTIBODY THERAPIES
  • NANOBODIES AND OTHER NOVEL FORMS OF ANTIBODIES
    • NANOBODIES
    • ANTIBODY FRAGMENTS
    • BISPECIFIC ANTIBODIES (BSABS)
      • Intrabody
    • INNOVATIONS IN ANTIBODIES
      • TABLE 5: NOVEL ADC-RELATED TECHNOLOGIES
    • DIFFENTIATING ASPECTS OF ADCS
      • Novel Cytotoxic Technology
      • Novel Conjugation Technology
        • TABLE 6: NOVEL ADC TECHNOLOGIES
    • PRODUCTION
      • TABLE 7: MANUFACTURERS IN THE ADC SPACE AND THEIR FOCUS

CHAPTER 4 - MARKET FORECAST FOR ADCS

  • PHARMACEUTICAL LANDSCAPE
    • TABLE 8: LEADING PHARMACEUTICAL COMPANY IN TERMS OF SALES, 2012 ($ BILLIONS)
    • FIGURE 2: REVENUES BY REGION IN THE PHARMACEUTICAL SECTOR, 2012
  • THE ADC MARKET LANDSCAPE
    • KEY DRIVERS
    • KEY CHALLENGES
    • ADC GROWTH AND ITS DISTRIBUTION
      • FIGURE 3: FORECAST FOR NUMBER OF U.S. FDA-APPROVED ADC DRUGS, 2011-2018 THROUGH 2018
      • FIGURE 4: ADC REVENUES BY REGION, 2013 AND 2018 (% OF TOTAL REVENUES)
      • FIGURE 5: REVENUES BY ADC TARGET ANTIGEN, 2013 AND 2018 ($ MILLIONS)
      • FIGURE 6: REVENUES BY ADC SPECIFIC CYTOTOXIN, 2013 AND 2018 ($ MILLIONS)
      • FIGURE 7: ADC BY THERAPEUTIC AREA, 2013 AND 2018 (% OF TOTAL COMMERCIALIZED ADCS)
      • FIGURE 8: ADC REVENUE BY THERAPEUTIC AREA, 2013 AND 2018 ($ MILLIONS)
  • REGULATORY FACTORS
  • INVESTMENT AND ALLIANCES
    • TABLE 9: MAJOR ADC INVESTMENTS AND ALLIANCES
  • DEVELOPMENT CONSIDERATIONS
  • PATENTING
  • PROMISING THERAPIES
    • CMC-544
    • RG7596
    • RG7593 (pinatuzumab vedotin)
    • CDX-011
    • PSMA ADC
    • SAR3419
    • BT-062
      • TABLE 10: ADC DRUGS IN THE DEVELOPMENT PIPELINE
      • FIGURE 9: ANTIGEN TARGETS FOR ADCS IN LATE DEVELOPMENT (%)
      • FIGURE 10: THERAPEUTIC FOCUS FOR ADCS IN LATE STAGE DEVELOPMENT (%)
      • TABLE 11: USEFUL RESOURCES FOR THE ADC DRUG INDUSTRY

CHAPTER 5 - COMPANY PROFILES

  • ABBVIE, INC. INC.
  • ABGENOMICS INTERNATIONAL, INC. INC.
  • ADC BIOTECHNOLOGY LTD.
  • ADC THERAPEUTICS
  • AFFINICON APS
  • AGENSYS, INC. INC.
    • ASTELLAS PHARMA US LLC
  • ALBANY MOLECULAR RESEARCH INC.
  • ALGETA ASA
  • ALLOZYNE
  • AMBRX INC.
  • AMGEN INC.
  • AQUITAINE PHARM INTERNATIONAL/PIERRE FABRE
  • AVIDBIOLOGICS, INC.
  • BAXTER HEALTHCARE CORPORATION.
  • BAYER HEALTHCARE PHARMACEUTICALS
  • BIND BIOSCIENCES, INC.
  • BIOGEN IDEC
  • BIOOUTSOURCE LTD.
  • BIOSYN
  • BIOTEST AG
  • BRISTOL MYERS SQUIBB
  • BSP PHARMACEUTICALS SRL
  • CARBOGEN AMCIS
  • CATALENT PHARMA SOLUTIONS
  • CELLDEX THERAPEUTICS, INC.
  • CELLTRION
  • CENTROSE
  • THE CHEMISTRY RESEARCH SOLUTION LLC
  • CYTOMX THERAPEUTICS, INC. INC.
  • DAIICHI SANKYO CO., LTD. (U.S.)
  • DALTON PHARMA SERVICES
  • ELI LILLY AND COMPANY
  • ESPERANCE PHARMACEUTICALS, INC. INC.
  • FABRUS, LLC
  • FIVE PRIME THERAPEUTICS, INC. INC.
  • FUJIFILM DISYNTH BIOTECHNOLOGIES
  • GENENTECH, INC
    • HOFFMANN-LA ROCHE, INC. INC.
      • TABLE 12: GENENTECH'S ADC PIPELINE
  • GENMAB A/S
  • GLAXOSMITHKLINE PLC
  • GOODWIN BIOTECHNOLOGY, INC. INC.
  • HEIDELBERG PHARMA GMBH
    • WILEX
  • IMAGINAB, INC. INC.
  • IMMUNOGEN, INC. INC.
  • IMMUNOMEDICS, INC. INC.
  • INTELLECT NEUROSCIENCES, INC. INC.
  • LAUREATE BIOPHARMACEUTICAL SERVICES, INC. INC.
  • LONZA GROUP LTD.
  • MEDIMMUNE LLC
    • ASTRAZENECA PLC
  • MENARINI BIOTECH
  • MERSANA THERAPEUTICS, INC. INC.
  • MILLENIUM PHARMACEUTICALS, INC
    • TAKEDA PHARMACEUTICAL COMPANY LTD.
  • MORPHOSYS
  • NBE THERAPEUTICS
  • NOVASEP
  • OXFORD BIOTHERAPEUTICS
  • PIRAMAL HEALTHCARE LTD.
  • PFIZER
  • PHILOCHEM
  • PHOTOBIOTICS, LTD.
  • POLYTHERICS
  • PROGENICS PHARMACEUTICALS, INC
  • SANOFI
  • SEATTLE GENETICS
  • SIGMA-ALDRICH SAFC
  • SORRENTO THERAPEUTICS, INC
  • SPIROGEN LTD.
  • STELLAR BIOTECHNOLOGIES, INC. INC.
  • SUTRO BIOPHARMA, INC. INC.
  • SYNTHON
  • UCB
  • VENTANA MEDICAL SYSTEMS, INC. INC.
    • HOFFMAN-LA ROCHE, INC. INC.
  • VIVENTIA BIOTECHNOLOGIES, INC. INC.
  • ZHEJIANG MEDICINE CO. LTD.

LIST OF TABLES

  • TABLE A FDA* APPROVAL PROCESS FOR NEW DRUGS
  • SUMMARY TABLE: GLOBAL FORECAST FOR ADC DRUGS* THROUGH 2018 ($ MILLIONS)
    • TABLE 1: KEY DATES IN ANTIBODY DEVELOPMENT
    • TABLE 2: CLASSES OF BIOPHARMACEUTICALS
    • TABLE 3: DOMINANT ADC TECHNOLOGY
    • TABLE 4: ADC CYTOTOXINS USED AND THEIR MODES OF ACTION
    • TABLE 5: NOVEL ADC-RELATED TECHNOLOGIES
    • TABLE 6: NOVEL ADC TECHNOLOGIES
    • TABLE 7: MANUFACTURERS IN THE ADC SPACE AND THEIR FOCUS
    • TABLE 8: LEADING PHARMACEUTICAL COMPANY IN TERMS OF SALES, 2012 ($ BILLIONS)
    • TABLE 9: MAJOR ADC INVESTMENTS AND ALLIANCES
    • TABLE 10: ADC DRUGS IN THE DEVELOPMENT PIPELINE
    • TABLE 11: USEFUL RESOURCES FOR THE ADC DRUG INDUSTRY
    • TABLE 12: GENENTECH'S ADC PIPELINE

LIST OF FIGURES

  • SUMMARY FIGURE GLOBAL FORECAST FOR ADC DRUGS* 2011-2018 ($ MILLIONS)
    • FIGURE 1: ADC ILLUSTRATED
    • FIGURE 2: REVENUES BY REGION IN THE PHARMACEUTICAL SECTOR, 2012
    • FIGURE 3: FORECAST FOR NUMBER OF U.S. FDA-APPROVED ADC DRUGS, 2011-2018 THROUGH 2018
    • FIGURE 4: ADC REVENUES BY REGION, 2013 AND 2018 (% OF TOTAL REVENUES)
    • FIGURE 5: REVENUES BY ADC TARGET ANTIGEN, 2013 AND 2018 ($ MILLIONS)
    • FIGURE 6: REVENUES BY ADC SPECIFIC CYTOTOXIN, 2013 AND 2018 ($ MILLIONS)
    • FIGURE 7: ADC BY THERAPEUTIC AREA, 2013 AND 2018 (% OF TOTAL COMMERCIALIZED ADCS)
    • FIGURE 8: ADC REVENUE BY THERAPEUTIC AREA, 2013 AND 2018 ($ MILLIONS)
    • FIGURE 9: ANTIGEN TARGETS FOR ADCS IN LATE DEVELOPMENT (%)
    • FIGURE 10: THERAPEUTIC FOCUS FOR ADCS IN LATE STAGE DEVELOPMENT (%)
Back to Top